Vical Incorporated Message Board
-
just sickens me to see this stock go down with phase 3 results being so close
and the worse part is the market is up. just a sad biotech
-
The reality id that it's doing down much more. It is a sad story and I wish I never owned this thing.
The P3 trial is an open label trial (not double blinded), therefore, the company knew all along how much allovection shipped at any time, and thus how many patients were still being treated. They do have a rough idea of the efficacy in the last 3 years or so. However, there is absolutely no insider buying (except the over allotment by Singer at 3.75 in the secondary offer). That said something. I will get rid of everything I got and invest somewhere else.
VJ stressed everywhere that they recruited healthier patients and I guess that why the patients liver longer. Recent reviews show that stage III, IVa-b (low phosphatase) patients that median survival is over 2 years.- 1 Reply to bioprogene
-
Bio, you are lying again. Shame on you.
The A7 P3 study is neither double-blinded per say, nor open label:
http://clinicaltrials.gov/ct2/show/NCT00395070?term=allovectin&rank=1
You've got your survival rates wrong too, but in a direction that is adverse to your assertion... at least your stupidity is amusing sometimes.
-
every trade is a sell at the bid. you couldnt own a bigger P.O.S if you tried...this is unacceptable action especially in this great mkt..
- 1 Reply to steph7750
-
OK. I assume you sold now and are moving on to greener pastures. Good luck
-
come on. buy more. it's a mind game
-